Guanfacine
Aggression
Maimonides Medical CenterSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Aggression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Washington University School of Medicine | Phase 4 | BBB |
Risperdal Washington University School of Medicine | Phase 4 | BB |
Intramuscular Olanzepine Christian Medical College, Vellore, India | Phase 3 | BB |
Haloperidol Christian Medical College, Vellore, India | Phase 3 | BB |
Promethazine Christian Medical College, Vellore, India | Phase 3 | BB |
View all 10 →
Same molecule, other indications
Guanfacine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →